将免疫检查点抑制剂（ICI）与血管内皮生长因子（VEGF）/VEGF受体（VEGFR）抑制剂相结合，对治疗多种实体肿瘤有效；然而，针对晚期胃/胃食管联合（G/GEJ）癌的证据有限。本回顾性研究纳入一中心于2018年11月1日至2021年3月31日期间，连续收治的病理学证实为人表皮生长因子受体2（HER2）阴性、晚期未切除或转移性的G/GEJ癌患者，接受编程性细胞凋亡蛋白1（PD-1）抑制剂及VEGFR-2抑制剂阿帕替尼治疗，辅助线治疗及以上。直至疾病进展或毒性不可耐受方停止治疗。我们研究了52例患者的数据。29例患者原发肿瘤部位是胃，23例是GEJ。使用的PD-1抑制剂包括卡瑞利珠单抗（n = 28），信蒂利单抗（n = 18），帕博利珠单抗（n = 3）和特瑞利珠单抗（n = 1），所有患者均每3周用200毫克，有1例患者接受托利帕利珠单抗（240毫克每3周）和尼伏单抗（每2周200毫克）。口服阿帕替尼每天250毫克，共28天。客观缓解率（ORR）为15.4％（95％置信区间[CI] 6.9-28.1），疾病控制率（DCR）为61.5％（95％CI 47.0-74.7）。在中位随访14.8个月后，中位无进展生存期（PFS）为4.2个月（95％CI 2.6-4.8），总生存期（OS）为9.3个月（95％CI 7.9-12.9）。12名患者出现了3-4级治疗相关不良事件（23.1％）。没有出现意外毒性或死亡。该试验证明，抗PD-1抗体和阿帕替尼联合治疗可安全有效地治疗先前接受过治疗的不可切除晚期或转移性G/GEJ癌患者。本文受版权保护。保留所有权利。

Combining immune checkpoint inhibitors(ICI) with vascular endothelial growth factor(VEGF)/VEGF receptor(VEGFR) inhibitors are effective in treating a number of solid tumors; however, evidence in advanced gastric/gastroesophageal junction(G/GEJ) cancer is limited. This retrospective study included consecutive patients who received a programmed cell death protein 1(PD-1) inhibitor plus the VEGFR-2 inhibitor apatinib, second-line or later to treat unresectable advanced or metastatic, histologically-proven, human epidermal growth factor receptor 2(HER2)-negative G/GEJ cancer in a single center between November 1, 2018 and March 31, 2021. Treatment was continued until the disease progressed or the toxicity became intolerable. We examined data from 52 patients. The primary tumor site was the stomach in 29 patients and the GEJ in 23 patients. PD-1 inhibitors administered included camrelizumab(n = 28), sintilimab(n = 18), pembrolizumab(n = 3), and tislelizumab(n = 1) and all patients were given 200 mg every 3 weeks(Q3W), and toripalimab(240 mg Q3W) and nivolumab(200 mg every 2 weeks) were given to 1 patient each. For 28 days, apatinib 250 mg was administered orally once a day. The objective response rate(ORR) was 15.4%(95 %confidence interval[CI]6.9-28.1), and the disease control rate(DCR) was 61.5%(95 %CI47.0-74.7). After 14.8 months of median follow-up, the median progression-free survival(PFS) was 4.2 months (95% CI 2.6-4.8), and the overall survival(OS) was 9.3 months(95%CI7.9-12.9). Twelve patients underwent grade 3-4 treatment-related adverse events(23.1%). There was no unexpected toxicity or death. This trial demonstrated combination therapy with an anti-PD-1 antibody and apatinib was effective and safe in patients with previously treated unresectable advanced or metastatic G/GEJ cancer. This article is protected by copyright. All rights reserved.This article is protected by copyright. All rights reserved.